HIGH-DOSE RITUXIMAB IN THE CONDITIONING REGIMEN BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED B-CELL LYMPHOMAS IS ASSOCIATED WITH REDUCED GVHD-RELATED DEATHS, BUT DID NOT IMPROVE DISEASE CONTROL

被引：0
|
作者：
Dodero, A. [1 ]
Spina, F. [1 ]
Sarina, B. [2 ]
Carniti, C. [1 ]
Patriarca, F. [3 ]
Carella, A. M. [4 ]
Levis, A. [5 ]
Bosi, A. [6 ]
Falda, M. [7 ]
Di Raimondo, F. [8 ]
Di Bartolomeo, P. [9 ]
Dalto, S. [1 ]
Bacigalupo, A. [10 ]
Rambaldi, A. [11 ]
Corradini, P. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Ematol, Milan, Italy
[2] Humanitas Canc Ctr, Ematol, Rozzano, Italy
[3] Univ Udine, I-33100 Udine, Italy
[4] IRCCS Casa Solievo della Sofferenza, San Giovanni Rotondo, Italy
[5] Osped Alessandria, Ematol, Alessandria, Italy
[6] Azienda Osped Univ Carreggi, Ematol, Florence, Italy
[7] Osped San Giovanni Battista Torino, Ematol, Turin, Italy
[8] Osepedale Ferrarotto, Ematol, Catania, Italy
[9] Osped Pescara, Ematol, Pescara, Italy
[10] Osped San Martino Genova, Ematol, Genoa, Italy
[11] Osped Papa Giovanni XXIII, Ematol, Bergamo, Italy
来源：
BONE MARROW TRANSPLANTATION | 2014年 / 49卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
PH-P393
引用
收藏
页码：S288 / S288
页数：1
相关论文
共 50 条
  • [1] High-dose rituximab in the conditioning regimen before allogeneic stem cell transplantation for relapsed lymphomas: protective role of the antibody on GvHD incidence
    Corradini, P.
    Sarina, B.
    Carniti, C.
    Patriarca, F.
    Carella, A.
    Levis, A.
    Bosi, A.
    Falda, M.
    Di Bartolomeo, P.
    Olivares, C.
    Gimondi, S.
    Rambaldi, A.
    Dodero, A.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S421 - S421
  • [2] High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect
    Dodero, Anna
    Spina, Francesco
    Sarina, Barbara
    Carniti, Cristiana
    Patriarca, Francesca
    Garella, Angelo Michele
    Levis, Alessandro
    Bosi, Alberto
    Falda, Michele
    Di Bartolomeo, Paolo
    Onida, Francesco
    Dalto, Serena
    Vendramin, Antonio
    Rambaldi, Alessandro
    Corradini, Paolo
    BLOOD, 2013, 122 (21)
  • [3] Reduced-intensity conditioning (RIC) with high-dose rituximab and allogeneic stem cell transplantation for relapsed CD20+lymphomas: good disease control with low incidence of chronic GVHD
    Dodero, A.
    Sarina, B.
    Milone, G.
    Patriarca, F.
    Bosi, A.
    Dominietto, A.
    Farina, L.
    Foa, R.
    Terruzzi, E.
    Onida, F.
    Rambaldi, A.
    Corradini, P.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S162 - S162
  • [4] Significant GVHD-related mortality after reduced intensity conditioning and allogeneic stem cell transplantation in high risk patients
    Schetelig, J
    Kröger, N
    Held, TK
    Krusch, A
    Zabelina, T
    Dubiel, M
    Thiede, C
    Ehninger, G
    Zander, A
    Siegert, W
    BONE MARROW TRANSPLANTATION, 2001, 27 : S281 - S282
  • [5] Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas
    Khouri, IF
    Saliba, RM
    Hosing, C
    Okoroji, GJ
    Acholonu, S
    Anderlini, P
    Couriel, D
    De Lima, M
    Donato, ML
    Fayad, L
    Giralt, S
    Jones, R
    Korbling, M
    Maadani, F
    Manning, JT
    Pro, B
    Shpall, E
    Younes, A
    McLaughlin, P
    Champlin, RE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2240 - 2247
  • [6] Hiccups and severe hyponatremia associated with high-dose cyclophosphamide in conditioning regimen for allogeneic stem cell transplantation
    Lazarevic, V.
    Hagg, E.
    Wahlin, A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (01) : 88 - 88
  • [7] Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen
    Dodero, Anna
    Patriarca, Francesca
    Milone, Giuseppe
    Sarina, Barbara
    Miceli, Rosalba
    Iori, Anna
    Barretta, Francesco
    Terruzzi, Elisabetta
    Mussetti, Alberto
    Pini, Massimo
    Bosi, Alberto
    Dominietto, Alida
    Cascavilla, Nicola
    Onida, Francesco
    Narni, Franco
    Farina, Lucia
    Rambaldi, Alessandro
    Corradini, Paolo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (07) : 1102 - 1109
  • [8] HIGH-DOSE VERSUS STANDARD-DOSE RITUXIMAB WITH BEAM IN AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN'S LYMPHOMAS (NHL)
    Srour, S. A.
    Lozano, S.
    Nieto, Y.
    Alousi, A. M.
    Popat, U. R.
    Quazilbash, M. H.
    Anderlini, P.
    Kebriaei, P.
    Shpall, E.
    Champlin, R. E.
    Hosing, C.
    HAEMATOLOGICA, 2016, 101 : 114 - 114
  • [9] High-dose versus standard-dose rituximab with BEAM in autologous stem cell transplantation (SCT) for relapsed aggressive b-cell non-Hodgkin's lymphomas (NHL).
    Srour, Samer Ali
    Khouri, Issa F.
    Nieto, Yago
    Popat, Uday R.
    Qazilbash, Muzaffar H.
    Anderlini, Paolo
    Kebriaei, Partow
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Hosing, Chitra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Immuno-chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation as treatment of advanced B-cell lymphomas in children
    Dyshlevaya, ZM
    Shelikhova, LS
    BONE MARROW TRANSPLANTATION, 2006, 37 : S243 - S243
12345